121 related articles for article (PubMed ID: 12439602)
1. Carboplatin hypersensitivity presenting as coronary vasospasm - a case report.
Chasen MR; Ebrahim IO
Cancer Chemother Pharmacol; 2002 Nov; 50(5):429-31. PubMed ID: 12439602
[TBL] [Abstract][Full Text] [Related]
2. Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinoma.
Ottaiano A; Tambaro R; Greggi S; Prato R; Di Maio M; Esposito G; Scala F; Barletta E; Losito S; De Vivo R; Iaffaioli VR; Pignata S
Anticancer Res; 2003; 23(4):3465-8. PubMed ID: 12926091
[TBL] [Abstract][Full Text] [Related]
3. Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience.
Polyzos A; Tsavaris N; Kosmas C; Arnaouti T; Kalahanis N; Tsigris C; Giannopoulos A; Karatzas G; Giannikos L; Sfikakis PP
Oncology; 2001; 61(2):129-33. PubMed ID: 11528251
[TBL] [Abstract][Full Text] [Related]
4. Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel.
Ozols RF; Bookman MA; du Bois A; Pfisterer J; Reuss A; Young RC
Gynecol Oncol; 2006 Oct; 103(1):1-6. PubMed ID: 16904166
[No Abstract] [Full Text] [Related]
5. Hypersensitivity reactions to carboplatin.
Planner RS; Weerasiri T; Timmins D; Grant P
J Natl Cancer Inst; 1991 Dec; 83(23):1763-4. PubMed ID: 1770557
[No Abstract] [Full Text] [Related]
6. Hypersensitivity reactions to intraperitoneal administration of carboplatin in ovarian cancer: the first report of a case.
Shukunami K; Kurokawa T; Kawakami Y; Kubo M; Kotsuji F
Gynecol Oncol; 1999 Mar; 72(3):431-2. PubMed ID: 10053120
[TBL] [Abstract][Full Text] [Related]
7. Bilateral irreversible hearing loss associated with the combination of carboplatin and paclitaxel chemotherapy: a unusual side effect.
Salvinelli F; Casale M; Vincenzi B; Santini D; Di Peco V; Firrisi L; Onori N; Greco F; Tonini G
J Exp Clin Cancer Res; 2003 Mar; 22(1):155-8. PubMed ID: 12725337
[TBL] [Abstract][Full Text] [Related]
8. [Successful desensitization using cisplatin after carboplatin-associated hypersensitivity reactions in 3 cases with recurrent ovarian carcinoma].
Hosaka M; Ebina Y; Moriwaki M; Hara Y; Araki N; Todo Y; Takeda M; Watari H; Sakuragi N
Gan To Kagaku Ryoho; 2007 Sep; 34(9):1505-8. PubMed ID: 17876157
[TBL] [Abstract][Full Text] [Related]
9. Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy.
de Jonge ME; Huitema AD; Tukker AC; van Dam SM; Rodenhuis S; Beijnen JH
Clin Cancer Res; 2005 Jan; 11(1):273-83. PubMed ID: 15671556
[TBL] [Abstract][Full Text] [Related]
10. Intraperitoneal therapy for ovarian cancer: why has it not become standard?
Rowan K
J Natl Cancer Inst; 2009 Jun; 101(11):775-7. PubMed ID: 19470952
[No Abstract] [Full Text] [Related]
11. A comparative study on hematological effects of carboplatin plus cyclophosphamide and carboplatin plus paclitaxel chemotherapy for the first line treatment of epithelial ovarian cancer.
Vapattanawong P
J Med Assoc Thai; 2006 Sep; 89(9):1357-61. PubMed ID: 17100369
[TBL] [Abstract][Full Text] [Related]
12. A case of bowel perforation after neoadjuvant chemotherapy for advanced epithelial ovarian cancer.
Carter J; Durfee J
Gynecol Oncol; 2007 Dec; 107(3):586-9. PubMed ID: 17949798
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients.
Navo M; Kunthur A; Badell ML; Coffer LW; Markman M; Brown J; Smith JA
Gynecol Oncol; 2006 Nov; 103(2):608-13. PubMed ID: 16797060
[TBL] [Abstract][Full Text] [Related]
14. Use of the collagen gel droplet embedded drug sensitivity test to determine drug sensitivity against ovarian mature cystic teratoma with malignant transformation to adenocarcinoma: a case report.
Yamagami W; Banno K; Kawaguchi M; Yanokura M; Kuwabara Y; Hirao N; Susumu N; Tsukazaki K; Aoki D
Chemotherapy; 2007; 53(2):137-41. PubMed ID: 17308380
[TBL] [Abstract][Full Text] [Related]
15. Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin--a Sankai Gynecology Study Group (SGSG) study.
Miyagi Y; Fujiwara K; Kigawa J; Itamochi H; Nagao S; Aotani E; Terakawa N; Kohno I;
Gynecol Oncol; 2005 Dec; 99(3):591-6. PubMed ID: 16095677
[TBL] [Abstract][Full Text] [Related]
16. [Tolerance induction in anaphylaxis to carboplatin].
Herzinger T; Behr J; Przybilla B
Dtsch Med Wochenschr; 2003 Jul; 128(30):1595-6. PubMed ID: 12884147
[No Abstract] [Full Text] [Related]
17. Paclitaxel, carboplatin, and oral etoposide as initial treatment for advanced ovarian carcinoma: a Minnie Pearl Cancer Research Network phase II trial.
Hainsworth JD; Kalman L; Castine M; Sylvester L; Greco FA
Gynecol Oncol; 2005 Apr; 97(1):200-5. PubMed ID: 15790459
[TBL] [Abstract][Full Text] [Related]
18. A case of pure-type ovarian squamous cell carcinoma for which combination chemotherapy consisting of paclitaxel and carboplatin was not effective.
Todo Y; Minobe S; Sasaki M; Yamamoto R; Sakuragi N
Gynecol Oncol; 2005 Apr; 97(1):223-7. PubMed ID: 15790463
[TBL] [Abstract][Full Text] [Related]
19. Intraperitoneal chemotherapy in ovarian carcinoma with the combination of carboplatin and 5-fluorouracil.
Polyzos A; Giannikos L; Agrafiotis A; Kazaz M; Zonas C; Sfikakis P
J Chemother; 1989 Jul; 1(4 Suppl):1220-1. PubMed ID: 16312842
[No Abstract] [Full Text] [Related]
20. Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma.
Safra T; Menczer J; Bernstein RM; Shpigel S; Matcejevsky D; Inbar MJ; Golan A; Grisaru D; Levy T
Gynecol Oncol; 2009 Aug; 114(2):215-8. PubMed ID: 19446318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
